Amphastar Pharmaceuticals (AMPH) risk factors, FY2024 10-K

Risks Relating to our Business and Industry

1. 01Our success depends on our ability to develop and/or acquire and commercialize additional pharmaceutical products
2. 02Our ability to develop new products and additional revenue streams depends upon our ability to invest ongoing revenue, borrow funds or raise additional capital when needed
3. 03Our success depends on the integrity of our supply chain, including multiple single source suppliers, the disruption of which could negatively impact our business
4. 04Underutilization of our manufacturing capacity could negatively impact our gross margins
5. 05Our current and future indebtedness has and may continue to adversely affect our operating results and cash flows
6. 06Our ability to make scheduled payments of the principal and interest when due, or to refinance our borrowings under the Credit Agreement and/or the 2029 Convertible Notes, will depend on our future performance, which is subject to economic, financial, competitive and other factors beyond our control
7. 07activities on desirable terms, which could result in a default under the Credit Agreement, the 2029 Convertible Notes or future indebtedness
8. 08Our outstanding loan agreements contain restrictive covenants that may limit our operating flexibility
9. 09The conditional conversion feature of the 2029 Convertible Notes, if triggered, may adversely affect our financial condition and operating results
10. 10If we fail to obtain exclusive marketing rights for our generic pharmaceutical products or fail to introduce these generic products on a timely basis, our revenues, gross margin and operating results may decline significantly
11. 11Our generic products face, and our generic product candidates will face, additional competitive pressures that are specific to the generic pharmaceutical industry
12. 12If the market for a reference brand product, such as Lovenox®, significantly declines, sales or potential sales of our generic and biosimilar products and product candidates may suffer and our business would be materially impacted
13. 13Health care providers may not be receptive to our products, particularly those that incorporate our proprietary drug delivery platforms
14. 14If we are unable to maintain our group purchasing organization relationships, our revenues could decline and future profitability could be jeopardized
15. 15Consolidation in the health care industry could lead to demands for price concessions or for the exclusion of some suppliers from certain of our markets, which could have an adverse effect on our business, financial condition or results of operations
16. 16Sales of our products may be adversely affected by the continuing consolidation of our customer base
17. 17If our business partners do not fulfill their obligations with respect to our distribution or collaboration agreements, our revenues and our business will suffer
18. 18We depend upon our key personnel, the loss of whom could adversely affect our operations. If we fail to attract and retain the talent required for our business, our business could be materially harmed
19. 19Our business may be adversely affected by challenging macroeconomic conditions globally resulting from pandemics or other public health outbreaks
20. 20We may be exposed to product liability claims and may not be able to obtain or maintain adequate product liability insurance
21. 21If serious adverse events or deaths are identified relating to any of our products once they are on the market, we may be required to withdraw our products from the market, which would hinder or preclude our ability to generate revenues
22. 22Any acquisitions of technologies, products and businesses may be difficult to integrate, could adversely affect our relationships with key customers and/or could result in significant charges to earnings
23. 23We may engage in acquisitions or strategic partnerships that could disrupt our business, cause dilution to our stockholders, reduce our financial resources, cause or to incur debt or assume contingent liabilities, and subject us to other risks
24. 24Charges to earnings resulting from acquisitions could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline
25. 25We may evaluate asset dispositions and other transactions that may impact our results of operations, and we may not achieve the expected results from these transactions
26. 26Significant balances of intangible assets, including goodwill, are subject to impairment testing and may result in impairment charges, which may materially and adversely affect our results of operations and financial condition
27. 27Counterfeit versions of our products could harm our patients and reputation
28. 28Our business and operations have been impacted in the past, and may be impacted in the future, in the event of system breach or failure
29. 29which may result in loss of data or the impairment of production and other supply chain processes, adversely affecting our business
30. 30Although we maintain cyber insurance coverage that may cover certain of our losses in connection with a security
31. 31We have incurred losses in the past and we may operate at a loss in future years while continuing to invest in developing and acquiring new products

Risks Relating to Regulatory Matters

1. 32The FDA approval process for changes to existing products (such as change of components or API supplier) is time-consuming and complicated, and we may not obtain the FDA approval required for such changes within the timeline we desire, or at all
2. 33manufacturing plants that are not operating in conformity with cGMP and stop shipments of potentially violative products and to prosecute companies and individuals for violations of the FFDCA
3. 34Clinical failure can occur at any stage of clinical development. The results of earlier clinical trials are not necessarily predictive of future results and any product candidate we advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval
4. 35If clinical studies for our product candidates are unsuccessful or significantly delayed, we will be unable to meet our anticipated development and commercialization timelines, which would have an adverse impact on our business
5. 36Even if our clinical trials and laboratory testing are completed as planned, their results may fail to provide support for approval of our products or for label claims that will make our products commercially viable
6. 37We are engaging in particle engineering for certain product candidates and there is no guarantee that we will obtain regulatory approval or, upon commercialization, market acceptance of these products
7. 38A fast track designation by the regulatory agencies, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval
8. 39The scientific foundation of our NDA product candidates will be based on our various proprietary technologies and the
9. 40Our ANDA products are also subject to FDA approval of their labeling and the labeling of the referenced drug products
10. 41Our investments in biosimilar products may not result in products that are approved by the FDA or other foreign regulatory authorities and, even if approved by such authorities, may not result in commercially successful products
11. 42Some of our products are used with drug delivery or companion diagnostic devices which have their own regulatory, manufacturing, reimbursement and other risks
12. 43If branded pharmaceutical companies are successful in limiting the use of generics through their legislative, regulatory and/or other efforts, our sales of generic products may suffer
13. 44Our revenues may be adversely affected if we fail to obtain insurance coverage or adequate reimbursement for our products from third-party payers and administrators
14. 45We must manufacture our drug products at our facilities in conformity with cGMP regulations; failure to maintain compliance with cGMP regulations may prevent or delay the manufacture or marketing of our products or product candidates and may prevent us from gaining approval of our products
15. 46Our operations are subject to environmental, health and safety and other laws and regulations, with which compliance is costly and which exposes us to penalties for non-compliance
16. 47The Affordable Care Act and certain legislation and regulatory proposals may increase our costs of compliance and negatively impact our profitability over time
17. 48The full impact of new laws and regulations and changes to any existing regulations by the current administration is uncertain. Some changes may have an adverse effect on our results of operations
18. 49Complying with laws in the U.S., Europe, and other jurisdictions that impose restrictive regulations addressing the collection, use, and other processing of personal information may be expensive, and failure to comply with such laws and regulations could cause substantial harm to our business
19. 50modify our compliance measures and incur costs
20. 51Our products may be subject to federal and state laws and certain initiatives relating to cost control, which may decrease our profitability
21. 52methodologies, these calculations are subject to the risk of errors. In addition, they are subject to review and challenge by the applicable governmental agencies, and it is possible that such reviews could result in material changes
22. 53We may be subject to enforcement action if we engage in the off-label promotion of our products
23. 54The pharmaceutical industry is highly regulated and pharmaceutical companies are subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act
24. 55Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements

Risks Relating to our International Business

1. 56We are exposed to risks related to our international operations and failure to manage these risks may adversely affect our operating results and financial condition
2. 57Adverse changes to import restrictions relating to certain animal-derived products or raw materials we use from affected countries could disrupt our supply chain and result in delays in the manufacturing of our products
3. 58Enhanced trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers may materially harm our business
4. 59We are subject to various governmental export control and trade sanctions laws and regulations that could impair our ability to compete in international markets or subject us to liability if we violate these controls
5. 60products, or provide related services, to certain countries and end-users, and for certain end-uses. The process for obtaining necessary licenses may be time-consuming or unsuccessful, potentially causing delays in sales or losses of sales opportunities and these licenses may not be issued
6. 61The Chinese government may exert substantial influence over the manner in which we conduct our business operations in China
7. 62The Chinese legal system can be uncertain and could limit the legal protections available to us
8. 63Our financial performance is impacted by the financial performance of our Chinese operating subsidiary, ANP
9. 64As a result of Russia's invasion of Ukraine, the U.S., the U.K. and the EU governments, among others, developed coordinated sanctions and export-control measure packages that continue to include increasing controls

Risks Relating to our Intellectual Property

1. 65Our success depends on our ability to obtain, protect, and enforce our intellectual property
2. 66uses our intellectual property confidentially, in-house, with no public disclosure
3. 67Enforcement of our intellectual property rights may not be pursued in some situations in which an alleged infringer may have a more dominant intellectual property position or for other business reasons
4. 68We have in the past and in the future may become involved in patent litigations or other intellectual property proceedings relating to our future product approvals, which could result in liability for damages or delay or stop our development and commercialization efforts
5. 69Our unpatented trade secrets, know-how, confidential and proprietary information and technology may be inadequately protected
6. 70There is a risk that our trade secrets, know-how, and other confidential and proprietary information and technologies could have been, or could, in the future, be shared by any of our former employees with, and be used to the benefit of, any company that competes with us
7. 71There can be no assurance of timely patent and trademark review and approval to minimize competition and generate sufficient revenues

Risks Related to Ownership of our Common Stock

1. 72Sales of substantial amounts of our common stock, or indications of an intent to sell, may cause our stock price to decline
2. 73for future issuance under our equity compensation plans. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline
3. 74We do not intend to pay dividends for the foreseeable future
4. 75While we have engaged in repurchases of our common stock, any future decisions to reduce or discontinue repurchasing our common stock pursuant to our previously announced repurchase program could cause the market price for our common stock to decline
5. 76Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management
6. 77These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current
7. 78Global macroeconomic conditions may negatively affect us and may magnify certain risks that affect our business
8. 79We could be materially and adversely affected by violations of the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws
9. 80Movements in foreign currency exchange rates could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline
10. 81Our results of operations can be adversely affected by labor shortages, turnover and labor cost increases
11. 82Failure to maintain adequate internal controls or to implement new or improved controls could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline
12. 83Changes in tax laws, tax rulings and other factors may have a significantly adverse impact on our effective tax rate and tax expense, which could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline
13. 84We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
14. 85Our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline
15. 86In addition, if the market for pharmaceutical company stocks or the stock market in general, experiences a loss of
16. 87The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain executive management and qualified board members
17. 88We may become involved in securities class action litigation that could divert management’s attention from our business and adversely affect our business and could subject us to significant liabilities
18. 89We may become involved in litigation that may materially adversely affect us